

SKYRIZI® (RISANKIZUMAB-RZAA) PRESCRIBER ORDER FORM

Patient Name:		Date of Birth:	Gender:	
Address:				
Phone:	Height:	<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight:	<input type="checkbox"/> lbs <input type="checkbox"/> kg

Clinical Information

Primary Diagnosis Description:	ICD-10 Code:
--------------------------------	--------------

Allergies: NKDA OR (List):

TB Evaluation Status:	<input type="checkbox"/> Patient has been evaluated for tuberculosis (TB) infection prior to starting Skyrizi® treatment
	<ul style="list-style-type: none">• Date of evaluation/risk assessment _____• Provide clinical documentation of evaluation completed and/or TB test results with this order form (as applicable)

Skyrizi® (Risankizumab-rzaa) Prescription

Skyrizi® (Risankizumab-rzaa) refill as directed x 1 year

Crohn's Disease

Induction Dose: IV: Infuse **600mg** over at least 1 hour at Week 0, Week 4, and Week 8.

Maintenance Dose: SUBQ: Inject **180mg** starting at week 12, and every 8 weeks thereafter. (NDC 00074-1065-01 preferred)

SUBQ: Inject **360mg** starting at week 12, and every 8 weeks thereafter. (NDC 00074-1070-01 preferred)

Ulcerative Colitis

Induction Dose: IV: Infuse **1200mg** over at least 2 hours at Week 0, Week 4, and Week 8.

Maintenance Dose: SUBQ: Inject **180mg** starting at week 12, and every 8 weeks thereafter. (NDC 00074-1065-01 preferred)

SUBQ: Inject **360mg** starting at week 12, and every 8 weeks thereafter. (NDC 00074-1070-01 preferred)

Ancillary Orders

Anaphylaxis Kit

If this is a 1st infusion dose, would you like Option Care Health to provide an anaphylaxis kit with the 1st dose?

Yes No

Dosage:

- Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SUBQ or IM x 1; repeat x 1 in 5 to 15 min PRN.

- Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement.

- 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis.

Skilled Nursing to establish peripheral IV access as needed to manage anaphylaxis.

Medication Orders

Other: _____

IV Flush Orders

• Peripheral: 0.9% Sodium Chloride 2 to 3 mL pre-/post-use.

• Implanted Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.

Lab Orders

No labs ordered at this time.

Other: _____

Skilled nurse to assess and administer and/or teach self-administration where appropriate via (IV/SUBQ) access device as indicated above.

Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year.

If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.

I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.

Prescriber Signature: _____ Date: _____

Prescriber Information

Prescriber Name:	Phone:	Fax:
------------------	--------	------

Address:	NPI:
----------	------

City, State:	Zip:	Office Contact:
--------------	------	-----------------

Fax completed form, insurance information, and clinical documentation to: 713-983-4647

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.

V 14.0 – 6 July 2026

Not valid for use for patients residing in Arizona, New York, and Wisconsin

Page 1 of 1

© 2026 All rights reserved.